OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant Presented ByProf. Matthew Goetz, Mayo Clinic Rochester, MN, USA TrialPhase 3, MONARCH 3 ConferenceESMO 2022 16 November, 2022 17:48